Home
Resources
Publications
Study Protocol for the MEXiletine Hydrochloride Administration Trial: A Placebo-Controlled, Randomised, Double-Blind, Multicentre, Crossover Study of Its Efficacy and Safety in Spinal and Bulbar Muscular Atrophy (MEXPRESS)

Study Protocol for the MEXiletine Hydrochloride Administration Trial: A Placebo-Controlled, Randomised, Double-Blind, Multicentre, Crossover Study of Its Efficacy and Safety in Spinal and Bulbar Muscular Atrophy (MEXPRESS)

Shinichiro Yamada, Atsushi Hashizume, Yasuhiro Hijikata, Tomonori Inagaki, Daisuke Ito, Fumie Kinoshita, Masahiro Nakatochi, Yumiko Kobayashi, Akihiro Hirakawa, Tomohiko Nakamura, Masahisa Katsuno

BMJ Open. 2018 Sep 11;8(9):e023041.

PMID: 30206090

Abstract:

Introduction:
Spinal and bulbar muscular atrophy (SBMA) is a slowly progressive neuromuscular disease. Cold exposure often leads to worsening of motor symptoms including paresis. Although mexiletine hydrochloride administration has been shown to be effective for the treatment of several muscular diseases, its effectiveness in SBMA has not been validated to date. The trial will test it as a symptomatic drug for cold paresis. This study is the first trial to evaluate the efficacy and safety of mexiletine hydrochloride administration in patients with SBMA.
Methods and analysis:
A placebo-controlled, randomised, double-blind, multicentre, crossover clinical trial will be conducted to assess the safety and efficacy of mexiletine hydrochloride in patients with SBMA. The eligible patients will be assigned randomly in a 1:1 ratio to two groups in a double-blind manner. Participants will take mexiletine hydrochloride (300 mg/day) or a placebo orally three times a day for 4 weeks (period 1). After a 1-week washout period, participants will take the other drug for 4 weeks (period 2). The primary endpoint is the difference in distal latencies between room temperature and cold exposure conditions.
Ethics and dissemination:
This study will be conducted in compliance with the Helsinki Declaration and the Ethical Guidelines for Medical and Health Research Involving Human Subjects by the Japanese government and has been approved by the ethics committee of Nagoya University Graduate School of Medicine, as a central institutional review board, and by each facility. The results will be disseminated in peer-reviewed journals and at scientific conferences.
Trial registration number:
UMIN000026150; Pre-results.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP5370014-A	Mexiletine hydrochloride		5370-01-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: